Low Dose IL-2 Efficacy in Rheumatoid Arthritis A novel biologic intervention trial has shown that subcutaneous, intermittent therapy with low-dose interleukin-2 (Ld-IL2) is potentially effective and safe in rheumatoid arthritis (RA). https://t.co/ycDgLT9EAA https://t.co/NJi48FZzAa